<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee MK</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>2047-2058</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241696</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(7)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>The standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall.&lt;h4>Methods&lt;/h4>27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-</pubmed_abstract><journal>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</journal><pubmed_title>Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.</pubmed_title><pmcid>PMC10241696</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>HHSN261200800043C</funding_grant_id><funding_grant_id>U01 CA233046</funding_grant_id><pubmed_authors>Dueck AC</pubmed_authors><pubmed_authors>Mitchell SA</pubmed_authors><pubmed_authors>Mendoza TR</pubmed_authors><pubmed_authors>Minasian LM</pubmed_authors><pubmed_authors>Mazza GL</pubmed_authors><pubmed_authors>Schrag D</pubmed_authors><pubmed_authors>Ginos BF</pubmed_authors><pubmed_authors>Rogak LJ</pubmed_authors><pubmed_authors>Langlais BT</pubmed_authors><pubmed_authors>Basch E</pubmed_authors><pubmed_authors>Thanarajasingam G</pubmed_authors><pubmed_authors>Lee MK</pubmed_authors><pubmed_authors>Bennett AV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.</name><description>&lt;h4>Purpose&lt;/h4>The standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall.&lt;h4>Methods&lt;/h4>27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-05-29T03:03:53.663Z</modification><creation>2025-02-19T02:38:12.101Z</creation></dates><accession>S-EPMC10241696</accession><cross_references><pubmed>36897529</pubmed><doi>10.1007/s11136-023-03374-5</doi></cross_references></HashMap>